Background: Radioiodine (RAI) lobe ablation in lieu of completion thyroidectomy is not
Introduction
Radioiodine (RAI) has been used in the post surgical treatment of well-differentiated thyroid cancer (DTC) for over 50 years. 1 While the indications and recommendations for its utilization have changed over time, current American Thyroid Association (ATA) and National
Comprehensive Cancer Network (NCCN) guidelines recommend RAI ablation in select patients after total thyroidectomy (TT). 2, 3 The role of RAI ablation after lobectomy (TL), however, is unclear. The 2009 ATA guidelines for the management of DTC state: "Ablation of the remaining lobe has been used as an alternative to completion thyroidectomy. It is unknown whether this approach results in similar long-term outcomes. Consequently, routine RAI ablation in lieu of completion thyroidectomy is not recommended." 2 Several small retrospective studies have described the use of RAI lobe ablation after TL as a safe and effective alternative to completion thyroidectomy in DTC. [4] [5] [6] [7] [8] Santra and colleagues studied the long-term outcomes of RAI lobe ablation in a cohort of 364 TL patients with DTC
and compared them to a group of 372 patients who underwent completion thyroidectomy and RAI remnant ablation. After a median follow-up of 5 years, recurrence-free, disease-free survival and cause-specific mortality were similar between the groups. 8 The authors concluded that RAI lobar ablation is a safe, simple, effective and less expensive alternative to completion thyroidectomy in patients with DTC. To our knowledge, there are no randomized studies or large retrospective studies that compare the outcomes of patients who undergo TL with or without postoperative RAI.
Using the National Cancer Database (NCDB), this study describes RAI utilization rates and factors associated with its use after TL in DTC. It also compares the overall survival of patients who underwent TL alone with that of patients who underwent TL followed by RAI.
Methods

Data source and patient acquisition
After obtaining institutional review board approval, patients >18 years of age diagnosed with DTC between 1998-2011 were identified in the National Cancer Database (NCDB) utilizing the Logistic regression was utilized to identify independent factors associated with utilization of RAI.
Kaplan-Meier analysis was used to determine overall survival, and to perform univariate analysis of the impact of RAI on overall survival; the log rank test was used to calculate Table 1 . The median age at diagnosis was 48 years, 79%
were women, and 66% were treated in community health care facilities. The predominant tumor histology was PTC (83%) and the median tumor size was 1cm. At the time of TL, 4% of patients had extrathyroidal extension, 4% had positive lymph nodes and <1% of patients had distant metastases.
Postoperative RAI was administered to 24% of patients. Demographics, clinical characteristics and pathologic features of patients who received RAI are compared to patients who did not receive RAI and displayed in Figure 1 . By log-rank analysis, overall survival was slightly greater in the RAI group at five (97% vs. 95%, p<0.001) and ten years (91% vs. 89%, p<0.001).
On multivariate cox proportional hazards regression (Table IV) 
Discussion
The results of this study provide insight into the utilization patterns of RAI for management of DTC after TL. Despite lack of guideline recommendations for the utilization of RAI after TL, this practice is prevalent in approximately one-quarter of patients undergoing TL in the current series and is consistent with the literature. 12 In fact, 10% of all RAI administered from 1998 to 2011, recorded in the NCDB, was given to patients who underwent TL. This study found that patients who are younger, those receiving care in community health facilities and those with larger tumors or advanced disease stage at presentation were more likely to receive RAI after TL.
Despite the lack of recommendations however, we also found a significant overall survival advantage of postoperative RAI after TL when compared to TL alone.
The current study demonstrates that more advanced disease is associated with increased utilization of RAI after TL. Tumors >1cm, Stage II and III disease, extrathyroidal extension and lymph node positive disease were all independently associated with RAI use. While it is expected that patients with more advanced disease receive additional care after TL, the current standard of care recommends completion thyroidectomy prior to RAI ablation or treatment. 2, 3 It is possible that practitioners are utilizing RAI lobe ablation to avoid a second thyroid procedure with its associated anesthetic and technical complications. On the other hand, RAI ablation in the setting of an intact lobe has been associated with delays in treatment and slightly higher elevation of thyroglobulin as well as increased risk of radiation thyroiditis, chronic sialoadenitis,
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9 odynophagia, and facial edema when compared to remnant ablation after total thyroidectomy secondary to the use of higher or multiple doses. [13] [14] [15] Complication data are not reported in the NCDB, however, and therefore cannot be analyzed using this dataset.
Age <45 years was also associated with increased utilization of RAI after TL. This finding is surprising since such patients tend to have low-risk disease and prolonged survival, even with advanced locoregional disease or large tumors. 16, 17 Neither the NCCN nor ATA guidelines have age-specific recommendations regarding the use of RAI. Several groups have reported a lack of survival advantage when RAI is utilized in patients <45 years of age in the presence of lymph node positive disease or large tumors. 3, 16, [18] [19] [20] In our series, subgroup analysis of patients <45 years of age also failed to show a significant difference in the overall survival of patients who underwent TL and RAI vs. those who underwent TL without RAI (data not shown).
Increased utilization of RAI after TL was also higher in community health facilities and in the mid-west region. Previous studies have shown that TL is performed at higher rates when compared to total thyroidectomy in community health facilities and by low volume surgeons. 12, 21 TL is also associated with lower complication rates when compared to total thyroidectomy and therefore, RAI is possibly being utilized in lieu of completion thyroidectomy. 21 In an analysis of RAI utilization, Haymart and colleagues demonstrated that the wide variation in RAI use in the United States could be explained by hospital type, case volume and other hospital characteristics. 9 The lack of strong evidence to support or refute the use of RAI after TL likely further contributes to its continued utilization and decreases guideline concordance.
On unadjusted analysis, RAI after TL conferred a small survival advantage compared to TL alone at 5 and 10 years of follow up. After controlling for a variety of covariates, however RAI was independently associated with a significantly improved survival. Consistent with previous M A N U S C R I P T
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10 studies, age >45, male gender, black race, larger tumor size, extrathyroidal extension and distant metastases were all associated with decreased overall survival. 2, 22, 23 Additionally, insurance status seems to greatly impact survival outcomes. While this is not the focus of this study, similar findings have been shown in other cancer types 24, 25 and warrant further investigation as an important disparity in health care delivery and outcomes.
This study is unique because it compares TL to TL and RAI. The finding of improved overall survival in the TL and RAI group may indicate that not all thyroid cancers should be treated with lobectomy alone or without RAI, and proper patient selection for treatment is paramount. Recent data have shown that RAI has little or no impact on disease specific survival in low or intermediate risk thyroid cancer patients (<4cm tumors, without extrathyroidal extension and clinically node negative disease). 19, 20, 26, 27 Furthermore, adjusted analysis of the NCDB and SEER databases comparing TL to total thyroidectomy have demonstrated that the extent of surgery fails to provide a survival advantage when based solely on cancer size 28 or in patients <45 years of age, with <4cm tumors and without distant metastases. 29 Due to these findings experts are advocating for a more selective approach to RAI utilization and the practice of always performing a total thyroidectomy to allow for RAI ablation is being reassessed. [26] [27] [28] [29] This study was underpowered to perform survival analysis by risk group to determine which patients benefitted the most from RAI after TL. Although the findings in this study do not definitively support the routine use of RAI after TL as an alternative to completion thyroidectomy and remnant ablation, a subset of patients undergoing TL may benefit from RAI. Studies comparing morbidity and oncologic outcomes of TL followed by RAI vs. total thyroidectomy with or without RAI in properly selected patients are needed to ultimately answer this question. In conclusion, nearly a quarter of patients undergoing thyroid lobectomy for definitive treatment of DTC will receive RAI. There appears to be a survival advantage of RAI after TL when compared to TL alone. Future studies comparing TL alone, RAI after TL, and RAI after total thyroidectomy are needed to further elucidate the role of RAI after TL and to identify the risks and benefits of this treatment approach. 
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